Achillion Pharma (ACHN) Reports Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178
Tweet Send to a Friend
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced the presentation of updated results from the ongoing phase 2 ‘604 Study’ being ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
